Interferon alfa-2a indications and usage: Difference between revisions
(Created page with "__NOTOC__ {{Interferon alfa-2a}} {{CMG}} ==Indications And Usage== Roferon-A is indicated for the treatment of chronic hepatitis C and hairy cell leukemia in patients 18...") |
No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 5: | Line 5: | ||
==Indications And Usage== | ==Indications And Usage== | ||
Roferon-A is indicated for the treatment of chronic | Roferon-A is indicated for the treatment of chronic hepatitis C and hairy cell leukemia in patients 18 years of age or older. In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) patients who are minimally pretreated (within 1 year of diagnosis). | ||
===For Patients With Chronic Hepatitis C=== | |||
Roferon-A is indicated for use in patients with chronic hepatitis C diagnosed by HCV antibody and/or a history of exposure to hepatitis C who have compensated liver disease and are 18 years of age or older. A liver biopsy and a serum test for the presence of antibody to HCV should be performed to establish the diagnosis of chronic hepatitis C. Other causes of hepatitis, including hepatitis B, should be excluded prior to therapy with Roferon-A.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ROFERON-A (INTERFERON ALFA-2A) INJECTION, SOLUTION [ROCHE PHARMACEUTICALS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4c918b02-f158-4f7c-8ecc-fd49574ec228#nlm34090-1 | publisher = | date = | accessdate = 9 January 2014 }}</ref> | |||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
Latest revision as of 14:00, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Indications And Usage
Roferon-A is indicated for the treatment of chronic hepatitis C and hairy cell leukemia in patients 18 years of age or older. In addition, it is indicated for chronic phase, Philadelphia chromosome (Ph) positive chronic myelogenous leukemia (CML) patients who are minimally pretreated (within 1 year of diagnosis).
For Patients With Chronic Hepatitis C
Roferon-A is indicated for use in patients with chronic hepatitis C diagnosed by HCV antibody and/or a history of exposure to hepatitis C who have compensated liver disease and are 18 years of age or older. A liver biopsy and a serum test for the presence of antibody to HCV should be performed to establish the diagnosis of chronic hepatitis C. Other causes of hepatitis, including hepatitis B, should be excluded prior to therapy with Roferon-A.[1]
References
- ↑ "ROFERON-A (INTERFERON ALFA-2A) INJECTION, SOLUTION [ROCHE PHARMACEUTICALS]". Retrieved 9 January 2014.
Adapted from the FDA Package Insert.